InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,555.74
(
-0.16%
)
US TECH 100
19,012.40
(
-1.10%
)
Dow Jones
40,358.09
(
-0.14%
)
Brent Oil
81.02
(
0.30%
)
Bitcoin
66,536.16
(
0.93%
)
Post# of 252658
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: dav1234 post# 160422

Monday, 04/29/2013 8:54:51 AM

Monday, April 29, 2013 8:54:51 AM

Post# of 252658

Incyte (INCY) is set to receive a $25M milestone payment from Novartis (NVS) as a Phase II clinical trial for INC280 formally gets underway. NVS has exclusive development and commercialization rights to the compound.

Way behind ARQL's tivantinib. How is INCY's MET inhibitor differentiated?

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up